Vimarsana
Biggest News Aggregation in the World

Optimal Biologically Active Dose News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Optimal Biologically Active Dose. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Optimal Biologically Active Dose Today - Breaking & Trending Today

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM - Vimarsana News

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM

/PRNewswire/ -- YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's first in vivo genome editing candidate...

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM - Vimarsana News

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM

SHANGHAI, Dec. 17, 2023 /PRNewswire/ — YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company’s first in vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM). The study by YolTech is a single-arm, open-label, dose-escalation clinical trial (Clinicaltrials.gov: […]

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM - Vimarsana News

First Patient Dosed in Clinical Trial of YOLT-201 for the Treatment of Hereditary ATTR-CM

YolTech Therapeutics today announced that the first patient has been dosed with YOLT-201, the company's first in vivo genome editing candidate being developed as a single dose, potentially curative therapy for hereditary transthyretin amyloidosis...